Therefore, in postmenopausal patients, an increased breast cancer risk is linked to the mutant GSTO2 genotype alone, whereas in premenopausal women, the combined presence of GSTP1 and GSTO2 may further elevate the risk. Here, GSTP1 is linked to breast cancer.